The US Food and Drug Administration’s latest report to Congress on opening a regulatory pathway for using cannabidiols in products other than drugs makes clear that an additional $5m to support the work that House appropriators propose for the agency’s fiscal 2021 budget is needed.
While the FDA’s second report in 2020 to Congress on its oversight of CBD manufacturing and marketing includes results...
Welcome to HBW Insight
Create an account to read this article
Already a subscriber?